Please assess the completion status of the following clinical trial:

Trial Title: Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for first cytotoxic chemotherapy cycle, regardless of the line of treatment, because of hematologic malignancies at intermediate or high risk of TLS (according to the TLS risk stratification, Cairo M et al, British Journal of Haematology, 2010)candidate to Allopurinol treatment or have no access to Rasburicase~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3~* Life expectancy \> 1 month~Exclusion Criteria:~* Patients known to be hypersensitive to Febuxostat or Allopurinol or to any of the components of the formulations~* Patients with sUA levels ≥ 10 mg/dL at randomization~* Patients receiving Febuxostat, Allopurinol or any other urate lowering therapy (e.g. Rasburicase, probenecid) within 30 days prior to randomization~* Patients with severe renal and/or hepatic insufficiency~* Patients with diagnosis of LTLS or CTLS at randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Febuxostat (Type: EXPERIMENTAL): Febuxostat for 7-9 days
- Allopurinol (Type: ACTIVE_COMPARATOR): Allopurinol for 7-9 days

Based on this trial design, predict the completion outcome and termination type (if applicable).